期刊文献+

卵泡期高孕激素状态下促排卵方案的临床应用及安全性 被引量:12

Clinical Application of PPOS Protocol and Its Safety
在线阅读 下载PDF
导出
摘要 控制性促排卵的关键在于抑制早发黄体生成激素峰(LH峰)对卵泡发育的负面影响。传统的促性腺激素释放激素(GnRH)激动剂或拮抗剂方案存在高卵巢过度刺激综合征(OHSS)发生率、高成本及使用不方便等缺点。2015年匡延平教授首次提出了卵泡期高孕激素状态下促排卵(progestin primed ovarian stimulation,PPOS)方案,该方案利用口服外源性孕激素抑制LH峰联合人绝经期尿促性腺激素(hMG)促排卵,已被证实在各种卵巢反应的人群中均能有效抑制早发LH峰,获得高质量的胚胎及满意的临床结局。目前临床应用于PPOS方案的孕酮类药物有醋酸甲羟孕酮、安琪坦及地屈孕酮。作为一种新兴的促排卵方案,其安全性也值得关注。现将该方案作用机制、适用人群、不同孕激素类药物使用效果、对卵母细胞及胚胎质量影响及子代出生安全性进行综述。 It is essential to block the adverse effects of premature LH surge on developmental oocyte in the process of the controlled ovulation stimulation. The traditional protocols of ovulation induction, such as gonadotropin-releasing hormone agonist and antagonist, have some disadvantages of increasing incidence of ovarian hyperstimulation syndrome, high cost and inconvenience. In 2015, Professor Kuang YP proposed the progestin primed ovarian stimulation protocol(PPOS), in which exogenous progesterone was used to inhibit LH peak, and to combine with human menopausal urinary gonadotropin(hMG) to stimulate ovulation. PPOS protocol had been proved to be effective in inhibiting premature LH peak, obtaining good quality embryos and satisfactory clinical outcomes in women with all kinds of ovarian reactions. At present, progesterone drugs used in PPOS protocol include medroxyproges acetate, utrogestan and dydrogesterone. It is also necessary to concern the security of PPOS protocol. We reviewed the mechanism of PPOS protocol, the application population, the effeciency of different progesterone drugs, the effects on the quantity and quality of oocytes retrieved and the clinical outcomes,as well as the safety of newborn.
作者 于潇 麻婷 张学红(审校) YU Xiao;MA Ting;ZHANG Xue-hong(The First Clinical Medical College of Lanzhou University,Lanzhou 730000,China;Reproductive Medicine Special Hospital of the First Hospital of Lanzhou University,Key Laboratory for Reproductive Medicine and Embryo of Gansu Province,Lanzhou 730000,China)
出处 《国际生殖健康/计划生育杂志》 CAS 2019年第6期489-492,共4页 Journal of International Reproductive Health/Family Planning
基金 甘肃省科技重大专项(092NKDA009) 甘肃省自然科学基金(18JR3RA338)
关键词 卵泡期 排卵诱导 卵母细胞 胚胎发育 孕酮 Follicular phase Ovulation induction Oocytes Embryonic development Progesterone
  • 相关文献

参考文献10

二级参考文献64

  • 1Macklon NS, Stouffer RL, Giudice LC, et al. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev, 2006, 27(2): 170-207.
  • 2Porter RN, Smith W, Craft IL, et al. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet, 1984, 2(8414):1284-5.
  • 3Fleming R, Adam AH, Barlow DH, et al. A new systematic treatment for infertile women with abnormal hormone profiles. Br J Obstet Gynaecol, 1982, 89(1):80-3.
  • 4Smitz J, Devroey P, Camus M, et al. The luteal phase and early pregnancy after combined GnRH-agonist/hMG treatment for superovulation in IVF or GIFT. Hum Reprod, 1988, 3 (5):585-90.
  • 5Huime JA, Homburg R, Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod, 2007, 22(11):2805-13.
  • 6Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril, 2003, 80(6): 1444-9.
  • 7Reichman DE, Zakarin L, Chao K, et al. Diminished ovarian reserve is the predominant risk factor for gonadotropin-re- leasing hormone antagonist failure resulting in breakthrough luteinizing hormone surges in in vitro fertilization cycles.Fertil Steril, 2014,102(1):99-102.
  • 8Cedrin-Dumerin I, Bstndig B, Pameix I, et al. Effects of oral contraceptive, synthetic progestogen or natural estrogen pre- treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. Hum Reprod, 2007, 22(1):109-16.
  • 9Kuang Y, Chen Q, Huang Q, et al. Luteal-phase ovarian stimulation case report: three-year follow-up of a twin birth. J IVF Reprod Med Genet, 2013, 1:106.
  • 10Kuang Y, Hong Q, Chen Q, et al. Luteal-phase ovarian stimu- lation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertil Steril, 2014, 101(1):105-11.

共引文献164

同被引文献106

引证文献12

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部